Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating income | — | -$488K |
| Net income | — | $4.19M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | — | -$1.02M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $17.0K | $223.00 |
| Total assets | $138K | $505M |
| Total liabilities | $255K | $17.8M |
| Shareholders' equity | -$117K | -$17.8M |
| Retained earnings | -$152K | -$17.8M |
| Shares (wtd avg diluted) | 14.4M | 13.7M |
Every figure is extracted from Drugs Made In America Acquisition II Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.